logo
Carney praises Canadian unity as Canada Day celebrations kick off

Carney praises Canadian unity as Canada Day celebrations kick off

Yahoo02-07-2025
In his first Canada Day address as prime minister, Mark Carney emphasized Canadian unity in a "changing" world.
"One hundred and fifty-eight years ago, a few provinces bet on the idea that they'd be stronger together than they ever could be apart. They were right, and so they became a new federation that's now grown into our strong, bilingual, multicultural and ambitious country," Carney said in his video address.
That unity includes writing the country's "next chapter" together "in true partnership with First Nations, Inuit and Métis."
The prime minister took a moment in the video to acknowledge the recent challenges the country has been facing.
"The world is changing. Old friendships are fraying, our economy is being buffeted by a trade crisis and our values are being tested by attacks on democracy and freedoms," he said.
In an interview with CBC's Catherine Cullen, Carney said "we'll see" if Canada and the U.S. can come to a trade deal by July 21, a previously agreed-upon deadline set by the two countries.
"We're doing what is necessary in order to get the best deal for Canadians. If we get the best deal for Canadians, we will agree to it. If we can't we won't — it's that simple," he told CBC.
Asked about a growing separatist movement in Alberta, Carney said he remembered tensions between Alberta and the federal government when he was growing up in the province.
"What happened is we came together, helped build the province … everyone coming together," he said. "Alberta's a great province and this is an even greater country. The same's going to happen again."
Carney noted in his address that Canadians have been uniting "in a more divided and dangerous world," pointing to his one Canadian economy plan as a way to push back against instability.
"This is the greatest nation on earth. Our destiny is to make it greater still — not by what we say, but by what we do. Happy Canada Day," said Carney.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Factbox-Healthcare firms see growing activist investor involvement in the past year
Factbox-Healthcare firms see growing activist investor involvement in the past year

Yahoo

timea minute ago

  • Yahoo

Factbox-Healthcare firms see growing activist investor involvement in the past year

(Reuters) -Activist investors have targeted major healthcare companies over the past year to push them to improve their performance, with some campaigns only coming to light after announcements of board changes. Below are some notable healthcare companies that came under activist pressure in the last 12 months. MEDTRONIC In August 2025, the medical device maker appointed two new independent directors to its board and created independent committees focused on improving its performance, after Elliott Investment Management took a large stake, making it one of the company's biggest shareholders. AVANTOR Engine Capital targeted the life sciences firm in August 2025, urging it to bring in new board directors, cut costs and even consider a sale. CHARLES RIVER LABORATORIES The contract research firm settled with Elliott Investment Management in May 2025 by agreeing to add four new board directors and launch a strategic review of the business. NOVO NORDISK Activist hedge fund Parvus Asset Management is building a stake in the company, as investors have grown concerned that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss drug market, the Financial Times reported in June 2025. Reuters has not independently verified the report. GERRESHEIMER London-based investment fund Asset Value Investors in June 2025 pressed the German medical packaging maker to find ways to restore its market value. AVI, with a 3.5% stake in Gerresheimer, said the company needs a new financial leadership to regain its credibility. ILLUMINA In March 2025, the gene-sequencing maker said activist investor Keith Meister would join its board. HENRY SCHEIN In January, private equity firm KKR built a large stake in the medical and dental supplies distributor and reached a deal to add members to the company's board. Henry Schein was also under pressure from other investors, including Ananym Capital Management. PFIZER Activist hedge fund Starboard Value in October 2024 called for management accountability for the company's underperformance. This month, Starboard increased its holding in the drugmaker to 8.5 million shares, which represented about 0.15% of the outstanding shares as of June end. KENVUE In October 2024, Starboard Value took a significant stake in the Band-Aid maker, criticizing the weak performance of its skin health segment, which houses Neutrogena, Aveeno and other brands. After a proxy battle, the companies reached a deal in early 2025 that gave Starboard CEO Jeffrey Smith and two independent directors board seats. CVS HEALTH In November, CVS Health added Glenview Capital's top boss and three others to its board as part of a deal with the hedge fund. The company had been under pressure from investors, including Glenview, to improve operations after missing financial targets several times due to rising medical costs in its health insurance business. Glenview reduced its stake in the company after CVS posted strong results in May. Sign in to access your portfolio

B2Gold Increases Position in Founders Metals
B2Gold Increases Position in Founders Metals

Yahoo

timea minute ago

  • Yahoo

B2Gold Increases Position in Founders Metals

Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Founders Metals Inc. (TSXV: FDR) (OTCQX: FDMIF) (FSE: 9DL0) ("Founders" or the "Company") announces that B2Gold Corp. ("B2Gold") has completed its obligations under the Shareholder Agreement by purchasing 1,170,000 common shares (the "Shares"), as outlined in the Company's November 5, 2024 press release. B2Gold purchased the Shares in the open market to fulfill its agreement and preserve its right to participate in future financings up to a maximum of 9.9% ownership. Together with its prior private placement subscriptions, B2Gold now holds ~6% of Founders' issued and outstanding common shares on a non-diluted basis. Colin Padget, President and CEO, commented: "B2Gold's decision to increase their position demonstrates strong confidence in Founders and the Antino Gold Project. Their continued investment reinforces our shared belief in Antino as a Tier 1 discovery, and we're pleased to have their ongoing support as we work to unlock the project's full potential and realize value for shareholders." About Founders Metals Inc. Founders Metals is a Canadian-based exploration company focused on advancing the Antino Gold Project located in Suriname, South America, in the heart of the Guiana Shield. Antino is 20,000 hectares and has produced over 500,000 ounces of gold from historical surface and alluvial mining to date1. The Company is systematically advancing one of Suriname's most promising gold exploration and development opportunities with drill-confirmed, district-scale potential. Founders is committed to responsible exploration, community engagement, and delivering long-term value to shareholders through technical excellence and strategic growth in the Guiana Shield. ON BEHALF OF THE BOARD OF DIRECTORS, Per: "Colin Padget" Colin PadgetPresident, Chief Executive Officer, and Director Contact Information Katie MacKenzie, Vice President, Corporate DevelopmentTel: 306 537 8903 | katiem@ Harp Gosal, Director, Investor RelationsTel: 236 301 4211 | harpg@ Cautionary Statement Regarding Forward-Looking Information This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including statements regarding the use of proceeds from the Company's recently completed financings and the Company's prospects. Forward-looking information can generally be identified by words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or variations indicating that certain actions, events or results "may", "could", "would", "might" or "will" occur or be achieved. Forward-looking statements are based on management's current expectations and reasonable assumptions but are subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results to differ materially from those expressed or implied, including: general business and economic uncertainties; exploration results; mining industry risks; and other factors described in the Company's most recent annual management discussion and analysis. Although the Company has attempted to identify important factors that could cause actual results to differ materially, other factors may cause results not to be as anticipated. There can be no assurance that forward-looking information will prove accurate, as actual results and future events could differ materially from those anticipated. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All material information on Founders Metals can be found at 12022 Technical Report - Antino Project; Suriname, South America. K. Raffle, BSc, P. Geo & Rock Lefrançois, BSc, To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Yahoo

timea minute ago

  • Yahoo

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store